de Wynter E A, Durig J, Cross M A, Heyworth C M, Testa N G
CRC Section of Haemopoietic Cell and Gene Therapeutics, Paterson Institute for Cancer Research, Manchester, United Kingdom.
Stem Cells. 1998;16(5):349-56. doi: 10.1002/stem.160349.
Macrophage inflammatory protein-1 alpha (MIP-1alpha) has been shown to have a role in the control of myeloid stem and progenitor cell proliferation. Recent evidence suggests that MIP-1alpha also has a stimulatory effect on proliferation of mature progenitors as well as an inhibitory effect on immature progenitors in vitro. We have compared the effect of MIP-1alpha on myeloid and erythroid colony formation of CD34+ cells isolated from bone marrow and cord blood. In the presence of MIP-1alpha, bone marrow granulocyte-macrophage-colony forming cells (GM-CFC) were inhibited over a dose range of 15 ng/ml to 500 ng/ml, and GM-CFC from cord blood CD34+ cells were stimulated over the same dose range. MIP-1alpha suppressed BFU-E colonies in both bone marrow and cord blood. Using thymidine suicide assays, the influence of MIP-1alpha on the cycling status of the cells was assessed. A good correlation between the effect of MIP-1alpha on colony formation and cell cycle progression was observed. These results suggest that there is a differential response to MIP-1alpha when bone marrow and cord blood CD34+ cells are compared. Using flow cytometry and a biotinylated human MIP-1alpha/avidin fluorescein conjugate, the expression of MIP-1alpha receptors on CD34+ cells was assessed. The data indicated that there was little quantitative difference in overall expression of receptors (82.9% versus 93%) from bone marrow or cord blood, respectively. However, when Northern blot analysis was used, mRNA for two different MIP-1alpha receptors CCR1 and CCR5 could be detected in bone marrow, but only CCR1 mRNA was seen in cord blood CD34+ samples. Therefore, the expression of different receptor subtypes on CD34+ cells may be responsible for the difference in MIP-1alpha responsiveness observed.
巨噬细胞炎性蛋白-1α(MIP-1α)已被证明在控制髓系干细胞和祖细胞增殖中发挥作用。最近的证据表明,MIP-1α在体外对成熟祖细胞的增殖也有刺激作用,而对未成熟祖细胞有抑制作用。我们比较了MIP-1α对从骨髓和脐带血中分离出的CD34+细胞的髓系和红系集落形成的影响。在MIP-1α存在的情况下,骨髓粒细胞-巨噬细胞集落形成细胞(GM-CFC)在15 ng/ml至500 ng/ml的剂量范围内受到抑制,而脐带血CD34+细胞来源的GM-CFC在相同剂量范围内受到刺激。MIP-1α抑制了骨髓和脐带血中的爆式红系集落形成单位(BFU-E)集落。使用胸腺嘧啶核苷自杀试验,评估了MIP-1α对细胞周期状态的影响。观察到MIP-1α对集落形成和细胞周期进展的影响之间有良好的相关性。这些结果表明,比较骨髓和脐带血CD34+细胞时,对MIP-1α存在差异反应。使用流式细胞术和生物素化的人MIP-1α/抗生物素蛋白荧光素缀合物,评估了CD34+细胞上MIP-1α受体的表达。数据表明,骨髓或脐带血来源的受体总体表达在数量上差异不大(分别为82.9%和93%)。然而,当使用Northern印迹分析时,在骨髓中可检测到两种不同的MIP-1α受体CCR1和CCR5的mRNA,但在脐带血CD34+样本中仅可见CCR1 mRNA。因此,CD34+细胞上不同受体亚型的表达可能是观察到的MIP-1α反应性差异的原因。